Compounds > sj733
Page last updated: 2024-11-13

sj733

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SJ733: antimalarial; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID89508529
CHEMBL ID4207489
SCHEMBL ID14871903
MeSH IDM000605088

Synonyms (23)

Synonym
SCHEMBL14871903
HY-19556
CS-8066
1424799-20-1
unii-vt3a7na96k
sj733
sj-733
(+)-sj733
VT3A7NA96K ,
DB12659
(3s,4s)-1-oxo-3-pyridin-3-yl-2-(2,2,2-trifluoro-ethyl)-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (3-cyano-4-fluoro-phenyl)-amide
(3s,4s)-n-(3-cyano-4-fluorophenyl)-1-oxo-3-(pyridin-3-yl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide
(+)-sj557733
(3s,4s)-n-(3-cyano-4-fluorophenyl)-1-oxo-3-pyridin-3-yl-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide
gtpl9723
(+)-sj000557733
sj000557733
Q27292006
MS-28639
CHEMBL4207489
vkcpfwktfzaoto-lewjyisdsa-n
EN300-22861442
AKOS040742855

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"Two multidose unboosted cohorts (n = 9) (SJ733, 300 mg and 600 mg daily for 3 days) followed by three single-dose boosted cohorts combining SJ733 (n = 18) (75-, 300-, or 600-mg single dose) with cobicistat (150-mg single dose) as a pharmacokinetic booster were evaluated in healthy volunteers (ClinicalTrials."( Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development.
Bebrevska, L; Branum, KC; Chalon, S; Dallas, RH; Flynn, PM; Freeman, BB; Gaur, AH; Gusovsky, F; Guy, RK; Hammill, JT; Heine, RN; John, E; Maki, N; McCarthy, JS; Ost, S; Panetta, JC; Patel, ND; Richardson, JL; Smith, AM; Stewart, TB; Tang, L; Yanagi, T, 2022)		1.39

Bioavailability

ExcerptReferenceRelevance
" Single dose PK studies of SJ733 in mice, rats, and dogs demonstrated appreciable oral bioavailability (60-100%), whereas SJ311 had lower oral bioavailability (mice 23%, rats 40%) and higher renal clearance (10-30 fold higher than SJ733 in rats and dogs), suggesting less favorable exposure in humans."( Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones.
Charman, SA; Chen, Y; Freeman, B; Guy, RK; Hammill, J; Holbrook, G; Mirsalis, JC; O'Loughlin, KG; Shackleford, DM; White, KL; Yang, L; Zhu, F, 2021)		0.92
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID1412522Antimalarial activity against GFP transfected Plasmodium berghei in ICR mouse engrafted with parasite infected erythrocytes assessed as reduction in parasitemia administered as po qd for 3 to 5 days post infection measured on day 3 to 30 by Giemsa stainin2018MedChemComm, Mar-01, Volume: 9, Issue:3
Recent updates in the discovery and development of novel antimalarial drug candidates.
AID1375190Antimalarial activity against wild type Plasmodium falciparum Dd22018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ
AID1412523Oral bioavailability in mouse at 15 mg/kg2018MedChemComm, Mar-01, Volume: 9, Issue:3
Recent updates in the discovery and development of novel antimalarial drug candidates.
AID1629028Selectivity ratio of EC50 for multi-drug resistant Plasmodium falciparum V1S to EC50 for chloroquine sensitive/sulfadoxine resistant Plasmodium falciparum 3D72016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides.
AID1629008Antimalarial activity against chloroquine sensitive/sulfadoxine resistant Plasmodium falciparum 3D7 infected in human erythrocytes assessed as reduction in parasite growth after 72 hrs by Sybr green dye based spectrophotometry2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides.
AID1412521Antimalarial activity against Plasmodium falciparum 3D7 0087/N9 in NODscid IL-2Rgammanull mouse engrafted with parasite infected human erythrocytes assessed as reduction in parasitemia administered via oral gavage starting from day 3 to day 6 post infecti2018MedChemComm, Mar-01, Volume: 9, Issue:3
Recent updates in the discovery and development of novel antimalarial drug candidates.
AID1629019Antimalarial activity against Plasmodium berghei NK65 ANKA infected in Swiss Webster mouse assessed as reduction in parasitemia at 200 mg/kg, po qd administered as single dose by Peters test2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides.
AID1629020Antimalarial activity against Plasmodium berghei NK65 ANKA infected in Swiss Webster mouse assessed as reduction in parasitemia at 50 mg/kg, po qd for 4 days by Peters test2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides.
AID1629025Selectivity ratio of EC50 for bc1 complex inhibitor resistant Plasmodium falciparum SB-1 A6 to EC50 for chloroquine sensitive/sulfadoxine resistant Plasmodium falciparum 3D72016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides.
AID1629023Toxicity in Swiss Webster mouse infected by Plasmodium berghei NK65 ANKA assessed as overt signs at 200 mg/kg, po qd administered as single dose2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides.
AID1779234Antimalarial activity against synchronous ring stage of Plasmodium falciparum Dd2 assessed as parasite growth inhibition incubated for 72 hrs by Griffith assay based fluorescence analysis2021European journal of medicinal chemistry, Oct-05, Volume: 221Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID1412524Oral bioavailability in Sprague-Dawley rat at 20 +/- 0.2 mg/kg administered via gavage as solution2018MedChemComm, Mar-01, Volume: 9, Issue:3
Recent updates in the discovery and development of novel antimalarial drug candidates.
AID1375187Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring ATP4 S358S mutant2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ
AID1629022Toxicity in Swiss Webster mouse infected by Plasmodium berghei NK65 ANKA assessed as overt signs at 50 to 200 mg/kg, po qd for 4 days2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides.
AID1629016Intrinsic clearance in CD-1 mouse liver microsomes after 0.5 to 4 hrs in presence of NADPH by UPLC-MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides.
AID1629015Half life in CD-1 mouse liver microsomes in presence of NADPH by UPLC-MS analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides.
AID1779239Selectivity index, ratio of IC50 for antimalarial activity against PfATP4 inhibitor SJ557733-resistant Plasmodium falciparum Dd2 to IC50 of antimalarial activity against Plasmodium falciparum Dd22021European journal of medicinal chemistry, Oct-05, Volume: 221Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID1412526Oral bioavailability in beagle dog at 3 mg/kg2018MedChemComm, Mar-01, Volume: 9, Issue:3
Recent updates in the discovery and development of novel antimalarial drug candidates.
AID1629027Selectivity ratio of EC50 for multi-drug resistant Plasmodium falciparum Tm90C2b to EC50 for chloroquine sensitive/sulfadoxine resistant Plasmodium falciparum 3D72016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides.
AID1629026Selectivity ratio of EC50 for mefloquine resistant Plasmodium falciparum D10 to EC50 for chloroquine sensitive/sulfadoxine resistant Plasmodium falciparum 3D72016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides.
AID1375195Resistance index, ratio of IC50 for drug-resistant Plasmodium falciparum Dd2 harboring ATP4 S358S mutant to IC50 for wild type Plasmodium falciparum Dd22018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ
AID1412525Oral bioavailability in Sprague-Dawley rat at 17 +/- 0.2 mg/kg administered via gavage as suspension2018MedChemComm, Mar-01, Volume: 9, Issue:3
Recent updates in the discovery and development of novel antimalarial drug candidates.
AID1629024Selectivity ratio of EC50 for multi-drug resistant Plasmodium falciparum K1 to EC50 for chloroquine sensitive/sulfadoxine resistant Plasmodium falciparum 3D72016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides.
AID1412527Oral bioavailability in beagle dog at 30 mg/kg2018MedChemComm, Mar-01, Volume: 9, Issue:3
Recent updates in the discovery and development of novel antimalarial drug candidates.
AID1779238Antiplasmodial activity against PfATP4 inhibitor SJ557733-resistant Plasmodium falciparum Dd2 assessed as reduction in parasite growth incubated for 72 hrs by Griffith assay based fluorescence analysis2021European journal of medicinal chemistry, Oct-05, Volume: 221Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (45.45)24.3611
2020's6 (54.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.44 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index24.72 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (9.09%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
amodiaquine
Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.. amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.		2.1310aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.6320aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
primaquine
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.		2.2510aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial
pyrimethamine
Maloprim: contains above 2 cpds		2.3110aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
adamantane
Adamantane: A tricyclo bridged hydrocarbon.		2.2510adamantanes;
polycyclic alkane
alpha-aminopyridine
alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.		2.2510
mefloquine
(-)-(11S,2'R)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (-)-(11S,2'R)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown.		2.3110[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanolantimalarial
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		2.25101,2,3-triazole
pyronaridine
[no description available]		7.7620aminoquinoline
wr 99210
BRL 6231: RN given refers to parent cpd; NM & N1 refer to HCl; synonym BRL 51084 refers to (mono-HBr); structure		3.2710
piperaquine
piperaquine : An aminoquinoline that is 1,3-di(piperazin-1-yl)propane in which the nitrogen at position 4 of each of the piperazine moieties is replaced by a 7-chloroquinolin-4-yl group.		2.2510aminoquinoline;
N-arylpiperazine;
organochlorine compound		antimalarial
puromycin
[no description available]		2.3110puromycinsantiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor
artenimol
[no description available]		2.3110
artesunate
artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether		2.6320artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
oz 439
artefenomel: an antimalarial ozonide; structure in first source		2.2510
cobicistat
[no description available]		9.72111,3-thiazoles;
carbamate ester;
monocarboxylic acid amide;
morpholines;
ureas		P450 inhibitor
nitd 609
NITD 609: an antimalarial and coccidiostat; structure in first source		2.6120
6-chloro-7-methoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl)quinolin-4(1h)-one
6-Chloro-7-methoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl)quinolin-4(1H)-one: structure in first source		3.6820
ferroquine
ferroquine: an antimalarial agent; structure in first source		2.2510
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.1710
Infections, Plasmodium
[description not available]		06.0951
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		18.0951
Plasmodium falciparum Malaria
[description not available]		05.4641
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		05.4641
Parasitemia
The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)		02.2510
Acute Liver Injury, Drug-Induced
[description not available]		02.2510
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		02.2510